Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a research report on Monday, March 10th. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Tenax Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Trading Down 3.4 %

Tenax Therapeutics stock opened at $5.14 on Tuesday. The firm has a market capitalization of $21.32 million, a P/E ratio of -0.97 and a beta of 1.88. The business has a 50-day moving average of $6.13 and a 200-day moving average of $5.70. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.34. Research analysts anticipate that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Tenax Therapeutics

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics in the fourth quarter valued at approximately $84,000. Geode Capital Management LLC grew its position in Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares in the last quarter. Millennium Management LLC acquired a new stake in Tenax Therapeutics in the 4th quarter valued at $166,000. Finally, Janus Henderson Group PLC bought a new stake in Tenax Therapeutics during the 4th quarter worth about $1,026,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.